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Abstract. Glutathione S-transferases (GST) are a family of enzymes involved in phase-II detoxification of endog-
enous and xenobiotic compounds. Polymorphisms in GST genes have been associated with susceptibility to different
diseases. In this study we determined the frequencies of polymorphisms in GSTM1, GSTT1, and GSTP1 in DNA of 138
children from Cameroon, presenting with uncomplicated malaria (N 19), malaria with minor complications (N 81),
or severe malaria (N  38). Analyses of GSTM1 and GSTT1 were performed using PCR-multiplex procedure, while
GSTP1 was done by PCR-RFLP. Subjects presenting with malaria with complications were found more often of the
GSTM1-null genotype (58–64%) as compared with those with uncomplicated malaria (32%), a difference that was
statistically significant. We conclude that the GSTM1-null genotype is associated with malaria with complications.
In severe malaria, release of oxygen free radicals and a
variety of pro-inflammatory cytokines can lead to increased
vascular permeability, leakage of colloid from intravascular
space, pathologic vasodilation, and myocardial depression
with ultimate hypovolemia and impaired organ perfusion. In
children with malaria, lipid peroxidation in both blood plasma
and erythrocytes is increased, while erythrocytic antioxidants
such as glutathione (GSH), catalase, and tocopherol were
shown to be lower in patients with malaria than in control
subjects.1 The intracellular parasite digests hemoglobin,
thereby releasing free ferroprotoporphyrin or heme, which in
the presence of oxygen oxidizes to ferriprotoporphyrin or
hemin. This process produces superoxide, which decomposes
into H2O2 and O2. Antimalarials like chloroquine and amo-
diaquine inhibit this reaction, thus building up a toxic con-
centration of ferro/ferriprotoporphyrin (FP) leading to para-
site death.2,3 Indeed, several studies have suggested that an
increase in oxidative stress in parasitized red blood cells
(RBCs) offers an advantage to parasite clearance rather than
exacerbating the pathology.2–4 Glucose-6-phosphate dehy-
drogenase (G6PD)-deficient individuals for instance, are par-
tially protected against malaria. G6PD is essential for
NADPH production, which reduces oxidized glutathione.
Glutathione as an antioxidant is required for growth of the
parasite2,5 but also for maintenance of the redox state of the
host cell. Altered redox metabolism of the host cells, particu-
larly the endothelial cells, may exacerbate disease complica-
tions, for example by enhancing endothelial damage, brain
inflammation, and development of cerebral malaria. Several
studies document escape of FP from the parasite’s food vacu-
ole with consequent damage to erythrocyte membrane
through oxidation of proteins and lipids with eventual lysis of
the host cell.6–8 To maintain the integrity of the erythrocyte
membrane, an efficient redox system is required. A number
of mechanisms are involved in the removal of reactive oxygen
species and maintenance of cellular redox state, among which
are the glutathione S-transferases (GSTs). GSTs are intracel-
lular proteins that detoxify electrophilic compounds of endog-
enous and exogenous origin by conjugating them with GSH,
predisposing them to export out of the cell by multi-drug
resistance proteins. In addition GSTs are also known to ex-
hibit glutathione peroxidase activity.
Human GSTs comprise a family of proteins, classified into
4 major classes: GST-alpha (GSTA), GST-mu (GSTM), GST-
theta (GSTT), and GST-pi (GSTP). Many studies in both
humans and laboratory animals have documented strong as-
sociations between impaired or deficient GST activity and
various diseases connected to oxidative stress injury. Such
diseases include lung cancer, acute leukemia, and many oth-
ers.9–11 However, there is no documented study on the asso-
ciation between genetic polymorphisms in GSTs associated
with loss of GST enzyme activities and malaria. Since malaria
pathology progresses with increasing oxidative stress, we hy-
pothesize that impaired GST activity would increase severity
of malaria pathology.
In this study we investigated the role of polymorphisms in
GSTM, GSTT, and GSTP in DNA of 138 hospitalized chil-
dren with mild, severe, and very severe malaria, which was
collected in Yaoundé, Cameroon at the Department of Pedi-
atrics of the Central Hospital and in the outpatient clinic of
the Messa Dispensary. The patients studied were enrolled
between February 1994 and October 1996.12 Blood of chil-
dren with symptomatic clinical malaria according to World
Health Organization (WHO) standards, aged between 8
months and 14 years attending the outpatient clinic or admit-
ted to the Central Hospital of Yaoundé, was collected after
informed consent was obtained. Children with clinical malaria
were admitted to the emergency room of the Department of
Pediatrics and were examined by the clinical staff. All chil-
dren underwent a complete physical examination and a thick
smear was made. Then the severity of malaria was assessed
according to WHO standards as mild/uncomplicated and se-
vere malaria. The severe malaria group was subdivided into
severe and very severe. Patients with coma (Blantyre score
< 3 13, N  30), respiratory distress (Marsh et al.14, N  9),
repeated convulsions (> 1, N  10), and/or severe anemia
(Hb < 5 g/dL, N  1) were categorized as very severe,
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whereas those only suffering from impaired consciousness
(Blantyre 3–4, N  72), hyperparasitemia (> 5%, N  1)
and/or hyperpyrexia (> 40°C, N  18) were categorized as
severe cases. The number of patients categorized in the
groups of mild/uncomplicated, severe, and very severe ma-
laria was 19 (average age 5.0; 10 female and 9 males), 81
(average age 4.8; 34 females, 44 males and 3 not recorded),
and 38 (average age 3.5; 16 females, 20 males and 2 not re-
corded), respectively.
For GSTM1 and GSTT1 null polymorphisms, no gene
products are detected. For GSTM1, primers were used as
described by Bröckmoller et al.15 Beta-globin primers were
included in the reaction mixture as an internal positive con-
trol. A 650-bp PCR product was expected for GSTM1 and
absence of this fragment indicated 2 null alleles. For GSTT1,
primers and methods were used following description by
Pemble et al.16, yielding a 480-bp fragment, absence of which
indicated the null genotype. The PCR was repeated for nega-
tive samples to confirm the results. Three GSTP1 genotypes
occur, resulting from a single point mutation that changes
Ile-105 to Val, yielding wild-type, heterozygous, and homozy-
gous mutant genotypes. The heterozygous form has reduced
enzyme activity while the homozygous mutant enzyme
showed even lower activity.17 The polymorphism detection is
based on an Alw261 PCR-RFLP and PCR primers were de-
signed as described by Watson et al.18
Results of the GST genotyping are depicted in Table 1.
Overall, 42% of the patients were of the GSTM1 (+) geno-
type, while 58% possessed the GSTM1-null (−) genotype. For
GSTT1, 64% of the patients possessed a functioning allele
(GSTT1 (+)) while 36% had the GSTT1-null (−) genotype.
For GSTP1, 31% of the samples were of the homozygous
wild-type genotype, 46% heterozygous, and 23% of the ho-
mozygous mutant genotype. There was a significant differ-
ence in the distribution of the GSTM1-null genotypes be-
tween uncomplicated patients and those with malaria with
minor complications and severe malaria (2 6.7, P 0.005;
2 3.5, P 0.031). The GSTT1 genotype in uncomplicated
malaria and malaria with minor complications was just sig-
nificantly different (2  2.9, P  0.045), but no significant
difference was observed for GSTT1 in uncomplicated malaria
versus severe malaria (2  0.4, P  0.26). Also in the
GSTP1 polymorphisms no significant differences were de-
tected. This study does not show any interaction between the
GST polymorphisms and the different malaria groups.
These findings indicate that subjects lacking the GSTM1
enzyme are significantly over-represented in the malaria with
minor complications/severe malaria groups as compared with
the uncomplicated falciparum malaria group, thus supporting
our hypothesis of involvement of GSTs in malaria pathogen-
esis. Because GSTM1 catalyzes conjugation of GSH to a wide
range of electrophiles, we suggest that GSTM1 is important
for prevention of malaria with minor complications by reduc-
tion of oxidative stress in malaria. Increase in oxidative stress
within the food vacuole of Plasmodium berghei helps to kill
this parasite as has been demonstrated by the action of chlo-
roquine and amodiaquine.19 On the other hand, oxidative
stress may increase oxidative damage of erythrocyte mem-
branes, reducing the deformability of the cells and ultimately
inducing removal and massive destruction of erythrocytes by
macrophages, leading to increase in severe anemia, occlusion
of peripheral microvasculature, cerebral pathology (hypoxia),
and cardiac injury observed in severe falciparum malaria.1
In a future study the need for measuring the allele fre-
quency in a control group is necessary. When comparing the
general distribution of the GSTM1 null genotypes in our pa-
tient group, however, with the documented distribution in
African populations, the percentage of GSTM1-null is very
high (58%). Other studies document 22–38% of GSTM1-null
individuals,20–22 which is in line with our results in the un-
complicated malaria group (32%), indicating that individuals
with the null phenotype might be more likely hospitalized
when suffering from malaria. In Caucasians, however,
GSTM1 is lacking in 50–63% of the population.20,22
In conclusion, we found an association between the
GSTM1-null genotype and malaria with minor complications/
severe malaria. It is important to perform additional large
studies in Africa, to further investigate the connection of
GSTs and malaria.
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